Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor

International Journal of Urology

Volumn 14, Issue 1, 2007, Pages 54-59

  Miki, Tsuneharu ^a   Mizutani, Yoichi ^a   Akaza, Hideyuki ^b   Ozono, Seiichiro ^c   Tsukamoto, Taiji ^d   Terachi, Toshiro ^e   Naito, Katsusuke ^f   Nonomura, Norio ^g   Hara, Isao ^h   Yoshida, Osamu ⁱ  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY   (Japan)

^f YAMAGUCHI UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Germ cell tumor; High dose; Peripheral blood stem cell transplantation (PBSCT); Testis

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; TUMOR MARKER;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG TOLERABILITY; FEVER; FOLLOW UP; GERM CELL TUMOR; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHABDOMYOLYSIS; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TESTICULAR NEOPLASMS; TIME FACTORS;

EID: 33845617701     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01655.x     Document Type: Article

References (24)

1. Einhorn LH. Treatment or testicular cancer: a new and improved model. J. Clin. Oncol. 1990; 8: 1777-81.
2. Bosl GJ, Motzer RJ. Medical progress: testicular germ-cell cancer. N. Engl. J. Med. 1997; 337: 242-53.
3. Birch R, Williams S, Cone A et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol. 1986; 4: 400-7.
4. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 1997; 15: 594-603.
5. Sonneveld DJ, Hoekstra HJ, van der Graaf WT et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification system during the cisplatin era. Cancer 2001; 91: 1304-15.
6. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J. Clin. Oncol. 1998; 16: 692-701.
7. Bower M, Newlands ES, Holden L, Rustin GJS, Begent RHJ. Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB/ACE chemotherapy. Ann. Oncol. 1997; 8: 477-83.
8. Germa-Lluch JR, Garcia-del-Muro X, Tabernero JM et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann. Oncol. 1999; 10: 289-93.
9. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Natl. Cancer Inst. 1993; 85: 1828-35.
10. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Clin. Oncol. 1997; 15: 2546-52.
11. Decartis MP, Wilkinson PM, Welch RS, Metzner M, Morgenstern GR, Dougall M. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumors: an effective first-line therapy with minimal toxicity. Ann. Oncol. 2000; 11: 427-34.
12. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J. Clin. Oncol. 1990; 8: 170-8.
13. Wolff SN, Johnson DH, Hainsworth JD, Greco FA. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study. J. Clin. Oncol. 1984; 2: 271-4.
14. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol. 1989; 7: 932-9.
15. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer. A Phase I/II Study. J. Clin. Oncol. 1994; 12: 1223-31.
16. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 1987; 316: 1435-40.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
18. Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur. J. Cancer 1992; 28: 86-91.
19. Fizazi K, Zelek L. Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann. Oncol. 2000; 11: 133-49.
20. Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur. Urol. 1993; 23: 213-17.
21. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched pair analysis. J. Clin. Oncol. 1999; 17: 3450-6.
22. Pico JL, Rosti G, Kramar A et al. A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol. 2005; 16: 1152-9.
23. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J. Clin. Oncol. 2003; 21: 4083-91.
24. Bhatia S, Abonour R, Porcu P et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J. Clin. Oncol. 2000; 18: 3346-51.